Bml se163 5000

The following primary antibodies were used in the present study: rabbit anti-Pan-Calcineurin A (2614, CST, USA), rabbit anti-Calcineurin A (ab3673, Abcam, USA), rabbit anti-β-Actin (4970, CST, USA), mouse anti-NF-200 (MAB5262, Chemicon, USA), mouse anti-GFAP (MAB3402, Chemicon, USA), goat anti-CGRP (ab36001, Abcam, USA), and lectin from Bandeiraea Simplicifolia-BSI-B4 FITC conjugate (L2895, Sigma-Aldrich, USA). The secondary antibodies included fluoresce in (FITC) Affinipure donkey anti-mouse IgG (715-095-150, Jackson ImmunoResearch, USA), Alex Fluor 488 AffiniPure donkey anti-goat IgG (705-545-003, Jackson ImmunoResearch, USA) and Cy3-conjugated donkey anti-rabbit IgG (711-165-152, Jackson ImmunoResearch, USA). The drugs included ulinastatin (Techpool Company, Guangdong, China) and exogenous CN (BML-SE163-5000, Enzo LifeSciences, USA). IL-10 ELISA kits (R1000, R&D Systems Inc, MN, USA) were used to measure IL-10.

An intraperitoneal (i.p.) injection of ulinastatin (Techpool Company, Guangdong, China) (10,000, 50,000, 100,000 U/kg) was administered once each day (8 AM) for seven days after L5-VRT. Control animals received an equivalent volume of the vehicle. An intrathecal (i.t.) injection of exogenous CN (BML-SE163-5000, Enzo LifeSciences, USA) (10 U/rat) was administered once each day for seven days.